MOTS-c vs Tesamorelin — a mitochondrial peptide and a releasing-hormone analogue
MOTS-c is a short peptide encoded within mitochondrial DNA, studied in metabolic and mitochondrial regulation. Tesamorelin is an analogue of growth-hormone-releasing hormone acting on an endocrine axis, and it is an FDA-approved prescription drug for one specific indication. They act through unrelated pathways and sit in entirely different regulatory categories.
This pairing comes from body-composition searches, where both names appear. The compounds themselves are about as unrelated as two entries in this catalogue can be.
Side by side
| MOTS-c | Tesamorelin | |
|---|---|---|
| Origin | Encoded within mitochondrial DNA | Synthetic GHRH analogue |
| Pathway | Mitochondrial and metabolic regulation | GHRH receptor, somatotropic axis |
| Evidence base | Predominantly preclinical | Registered clinical trials for one indication |
| Regulatory status | Not approved | FDA-approved, one indication |
The evidence bases are not comparable
Tesamorelin's literature includes registered trials with declared endpoints, which anyone can look up. MOTS-c's is largely preclinical. That difference does not make one compound better than the other — it makes the two bodies of work impossible to weigh on a single scale.
What is worth checking
- Whether cited research is preclinical or clinical, and for which endpoint.
- Whether the certificate names an independent analysing laboratory.
- Whether a chromatogram accompanies the purity figure.
- Whether the lot on the certificate matches the lot on the vial.
The compounds discussed here
Go deeper
Frequently asked questions
- Do MOTS-c and Tesamorelin work on the same system?
- No. MOTS-c is studied in mitochondrial and metabolic regulation; Tesamorelin acts at the GHRH receptor on the somatotropic axis. There is no shared pathway and no published head-to-head work.
- Why is Tesamorelin treated differently commercially?
- It is an approved pharmaceutical. Approved drugs are refused by Google Merchant Center and restricted by most payment processors, which constrains how it can be listed and advertised regardless of the molecule itself.
- Which has more human data?
- Tesamorelin, by a wide margin — approval requires registered clinical trials. That is a statement about the evidence available for one specific indication, not a general claim about either compound.
References
Primary literature for the compounds above. Links open the record on PubMed.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Falutz J, et al. J Acquir Immune Defic Syndr. 2010. PMID 20101189 → · summary
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV Falutz J, et al. N Engl J Med. 2007. PMID 18057338 → · summary
- The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity Kim SJ, et al. Physiol Rep. 2019. PMID 31293078 → · summary
- The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Lee C, et al. Cell Metab. 2015. PMID 25738459 → · summary
- The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Lee C, et al. Cell Metab. 2015. PMID 25738459 → · summary